Journal of Biological Chemistry
Volume 275, Issue 22, 2 June 2000, Pages 16618-16625
Journal home page for Journal of Biological Chemistry

MOLECULAR BASIS OF CELL AND DEVELOPMENTAL BIOLOGY
Transferrin Receptor 2-α Supports Cell Growth Both in Iron-chelated Cultured Cells and in Vivo *

https://doi.org/10.1074/jbc.M908846199 Get rights and content
Under a Creative Commons license
open access

In most cells, transferrin receptor (TfR1)-mediated endocytosis is a major pathway for cellular iron uptake. We recently cloned the human transferrin receptor 2 (TfR2) gene, which encodes a second receptor for transferrin (Kawabata, H., Yang, R., Hirama, T., Vuong, P. T., Kawano, S., Gombart, A. F., and Koeffler, H. P. (1999) J. Biol. Chem. 274, 20826–20832). In the present study, the regulation of TfR2 expression and function was investigated. A select Chinese hamster ovary (CHO)-TRVb cell line that does not express either TfR1 or TfR2 was stably transfected with either TfR1 or TfR2-α cDNA. TfR2-α-expressing cells had considerably lower affinity for holotransferrin when compared with TfR1-expressing CHO cells. Interestingly, in contrast to TfR1, expression ofTfR2 mRNA in K562 cells was not up-regulated by desferrioxamine (DFO), a cell membrane-permeable iron chelator. In MG63 cells, expression of TfR2 mRNA was regulated in the cell cycle with the highest expression in late G1 phase and no expression in G0/G1. DFO reduced cell proliferation and DNA synthesis of CHO-TRVb control cells, whereas it had little effect on TfR2-α-expressing CHO cells when measured by clonogenic and cell cycle analysis. In addition, CHO cells that express TfR2-α developed into tumors in nude mice whereas CHO control cells did not. In conclusion, TfR2 expression may be regulated by the cell cycle rather than cellular iron status and may support cell growth bothin vitro and in vivo.

Cited by (0)

Published, JBC Papers in Press, March 9, 2000, DOI 10.1074/jbc.M908846199

*

This work was supported in part by grants from the National Institutes of Health, United States Department of Defense, California Tobacco Grant, C. and H. Koeffler Fund, Parker Hughes Trust, and an Eli Lilly International Fellowship (to H. K.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**

Holds the Mark Goodson endowed chair of oncology at Cedars-Sinai Medical Center and is a member of the Jonsson Cancer Center of UCLA.